Navicixizumab (Anti-DLL4)

Ask supplier a question | View on supplier's website

Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.

Supplier	Selleck Chemicals
Product #	A2519
Sku #	A2519-1mg*25
Pricing	1mg*25, $5070.00

Feedback